Kymera Therapeutics, Inc. (KYMR) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Kymera Therapeutics, Inc. (KYMR): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 44/100 — a percentile rank of Kymera Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $9.2B |
| P / S | 87.2× |
| EV / EBITDA | -26.7× |
| Gross margin | 100.0% |
| Operating margin | -333.6% |
| Net margin | -285.3% |
| Return on equity | -19.9% |
| ROIC | -25.2% |
| Revenue growth | 134.8% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is Kymera Therapeutics, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Kymera Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact